University of Oslo studying intranasal delivery of oxytocin; Sancilio Pharma files for IPO worth up to $86M;

> Researchers at the University of Oslo are collaborating with Optinose for the intranasal delivery of oxytocin, which research shows helps to improve perception of social cues, making it potentially useful among autistic patients. More

> Sancilio Pharmaceuticals just filed with the SEC to raise up to $86 million in an IPO on the Nasdaq. It licenses and develops products based on its lipid drug delivery technology. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.